NCT03510104: Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Sponsor: Meryx, Inc.. Phase: PHASE1. Conditions: Advanced Cancer, Metastatic Cancer, Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes